KalVista: Filling the VEGF void

KalVista developing kallikrein inhibitors for diabetic macular edema

KalVista Pharmaceuticals Ltd. believes its small molecule plasma kallikrein inhibitors will treat diabetic macular edema on par with VEGF inhibitors and will work in more patients. The biotech also hopes to offer injectable and oral delivery options for clinicians.

Diabetic macular edema (DME) is caused by increased permeability of the retinal vasculature, which results in fluid accumulation in the macula and ultimately vision loss.

First-line therapy includes laser-induced retinal photocoagulation, which can slow or reverse disease progression and reduce

Read the full 776 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE